Conditions: Rheumatoid Arthritis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 49
Healthy volunteers: no

Brief summary:
This open-label, single arm, multicenter long-term extension study of WA19926 evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who completed the 104-week WA19926 core study. Eligible patients received tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Tocilizumab
Intervention descriptions: intervention 1: 8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks

Protocol document: